New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
70
TL;DR: This review highlights key strategies for generating candidate SARS-CoV-2 vaccines and considerations for vaccine development and clinical trials.
read more
About: This article is published in Vaccine. The article was published on 08 Jan 2021. and is currently open access.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Raquel Cid,Jorge Bolivar +1 more
- 21 Jul 2021
TL;DR: The earliest vaccines were developed as live-attenuated or inactivated pathogens, and although they still represent the most extended human vaccine types, they also face some issues, such as the potential to revert to a pathogenic form of liveattenuated formulations or the weaker immune response associated with inactivated vaccines as mentioned in this paper.
95
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Ahmed I. Abulsoud,H. M. El-Husseiny,Ahmed A. El-Husseiny,Hesham A. El-Mahdy,Ahmed Ismail,Samy Y. Elkhawaga,Emad Gamil Khidr,Doaa Fathi,E. A. Mady,Agnieszka Najda,Mohammad Algahtani,Abdulrahman Theyab,Khalaf F. Alsharif,Ashraf Albrakati,Roula Bayram,Mohamed M. Abdel-Daim,Ahmed S. Doghish +16 more
TL;DR: In this paper , a review of SARS-coronavirus-2 pathophysiology and evolution approaches in altered transmission platforms and how they influence the virus characteristics is presented.
82
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Kuldeep Dhama,Manish Dhawan,Ruchi Tiwari,Talha Bin Emran,Saikat Mitra,Ali A. Rabaan,Saad Alhumaid,Zainab Al Alawi,Abbas Al Mutair +8 more
TL;DR: The current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic are highlighted.
70
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination.
TL;DR: In this paper, a review summarizes the main knowledge that we have about the humoral immune response during the ongoing pandemic of coronavirus disease 2019 (COVID-19) or after vaccination.
66
An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory
Ole Audun Werner Haabeth,Julian J K Lohmeyer,Adrienne Sallets,Timothy R. Blake,Idit Sagiv-Barfi,Debra K. Czerwinski,Blaine G. McCarthy,Abigail E. Powell,Paul A. Wender,Robert M. Waymouth,Ronald Levy +10 more
TL;DR: In this paper, an alternative mRNA vaccine approach using a delivery vehicle called charge-altering releasable transporters (CARTs) has been proposed to tailor the vaccine immunogenicity by inclusion of co-formulated adjuvants such as oligodeoxynucleotides with CpG motifs (CpG-ODN).
52
References
Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena L Loerks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann-Kathrin Eller,Jan Gruetzner,Carsten Boesler,Corinna Rosenbaum,Marie-Cristine Kuehnle,Ulrich Luxemburger,Alexandra Kemmer-Brueck,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Oezlem Tuereci +41 more
TL;DR: The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19.
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
Katie J. Ewer,Sarah Sebastian,Alexandra J. Spencer,Sarah C. Gilbert,Adrian V. S. Hill,Teresa Lambe +5 more
TL;DR: The 2014–15 Ebola outbreak in West Africa highlighted the potential for large disease outbreaks caused by emerging pathogens and has generated considerable focus on preparedness for future epidemics, and work is already underway to develop vaccines against a number of other outbreak pathogens.
78
Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the “Confined Virus”?
Tarek Alouane,Meriem Laamarti,Abdelomunim Essabbar,Mohammed Hakmi,El Mehdi Bouricha,M. W. Chemao-Elfihri,Souad Kartti,Nasma Boumajdi,Houda Bendani,Rokia Laamarti,Fatima Ghrifi,Loubna Allam,Tarik Aanniz,Mouna Ouadghiri,Naima El Hafidi,Rachid El Jaoudi,Houda Benrahma,Jalil El Attar,Rachid Mentag,Laila Sbabou,Chakib Nejjari,Saaïd Amzazi,Lahcen Belyamani,Azeddine Ibrahimi +23 more
TL;DR: Analysis of complete SARS-CoV-2 genomes from 79 countries located in the six continents and collected from 24 December 2019, to 13 May 2020 revealed the presence of 3206 variant sites, with a uniform distribution of mutation types in different geographic areas.
73
Egg-Independent Influenza Vaccines and Vaccine Candidates
Ilaria Manini,Claudia Maria Trombetta,Giacomo Lazzeri,Teresa Pozzi,Stefania Rossi,Emanuele Montomoli +5 more
TL;DR: Although the production of egg-derived vaccines will continue, new technological developments have generated a cell-culture-based influenza vaccine and other more recent platforms, such as synthetic influenza vaccines.
71
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery.
TL;DR: The longevity of specific antibodies against SARS-CoV-2 is estimated, and reported antibodies disappeared in a moderate COVID-19 patient within 3 months after the onset of the symptoms.
64
Related Papers (5)
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more